Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
11 nov. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Investor Conferences
10 nov. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Oral Data at CHEST 2015
23 oct. 2015 09h24 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update
22 oct. 2015 07h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2015 Financial Results
19 oct. 2015 08h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
16 oct. 2015 07h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete
Rolling NDA...
Cempra to Present Solithromycin Data at ID Week 2015
05 oct. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
24 sept. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
18 sept. 2015 07h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Data From Antibiotic Drug Development Programs at ICAAC/ICC 2015 Meeting
10 sept. 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...